Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lucid Group Inc (LCID) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Lucid Group IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Lucid Group Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M), while Lucid Group Inc trades at $6.52 (market cap $2.64B). The key difference: Lucid Group Inc is far larger — about 5.2× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.

DNALCID
Market Cap
$505.73M$2.64B
Sector
HealthConsumer Cyclical
52-Week High
$16.14$24.77
52-Week Low
$5.48$4.62
Enterprise Value
$607.68M$5.54B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Lucid Group Inc

Lucid (LCID) trades at $6.495, down 1.74% on the day, amid a bearish technical signal and weak fundamentals. The company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by negative gross and net income margins. Recent news highlights an operational reset targeting $1.4 billion in cash savings and a delayed EV launch, reflecting ongoing challenges in the competitive EV market.

The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus suggests modest upside to a $10.50 price target. Investment opportunities hinge on successful cost-cutting and robotaxi initiatives, while risks include execution missteps and intense competition. With 66.7% of analysts rating Hold, cautious optimism is tempered by financial instability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID